Vaccinex (VCNX) Stock Price, News & Analysis

Company Overview

Vaccinex, Inc. (NASDAQ:VCNX) is a clinical-stage biotechnology company dedicated to developing novel antibody-based therapies that modulate the immune system for the treatment of cancer, neurodegenerative disorders and fibrotic diseases. Since its founding in 2000, Vaccinex has focused on translating scientific discoveries into therapeutic candidates by leveraging a deep understanding of the tumor microenvironment and immune signaling pathways. The company’s research centers on creating targeted biologics designed to inhibit key regulatory proteins that contribute to disease progression and impaired immune surveillance.

The company’s lead program, pepinemab (formerly VX15/2503), is a humanized monoclonal antibody against semaphorin 4D (SEMA4D), a protein implicated in tumor growth, metastasis and neuroinflammation. Pepinemab is being evaluated in both oncology indications—including metastatic solid tumors and head and neck cancers—and in neurodegenerative conditions such as Huntington’s disease. Vaccinex has completed several Phase 1 and Phase 2 clinical trials, demonstrating safety, tolerability and early signs of clinical benefit, and plans to advance pepinemab in multi-center pivotal studies.

Vaccinex’s proprietary Scorpion™ antibody platform enhances the affinity and functional activity of therapeutic antibodies by optimizing Fc receptor engagement and epitope targeting. This platform has yielded multiple preclinical candidates and supports the company’s ambition to build a diversified pipeline of immuno-modulatory agents. In addition to pepinemab, Vaccinex is advancing next-generation molecules against novel targets in fibrotic lung disease and other solid tumor settings, backed by robust in vivo and in vitro validation studies.

Headquartered in Rochester, New York, Vaccinex operates state-of-the-art research and development facilities and collaborates with academic institutions, contract research organizations and biotechnology partners worldwide. Under the leadership of President and CEO William Hearl, the company pursues strategic partnerships to accelerate clinical development and expand its global footprint. With a focus on rigorous science and patient-centric innovation, Vaccinex aims to bring transformative therapies to individuals affected by serious diseases.

Key Stats

• Today's Range: $0.91 to $0.91
• 50-Day Range: $0.66 to $1.04
• 52-Week Range: $0.25 to $8.90
• Volume: 202 shs
• Average Volume: 53,653 shs
• Market Capitalization: $2.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Vaccinex Stock Analysis - MarketRank™

Vaccinex scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vaccinex.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaccinex is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaccinex is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of Vaccinex has been sold short.

Short Interest Ratio / Days to Cover

Vaccinex has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vaccinex has recently decreased by 20.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaccinex does not currently pay a dividend.

Dividend Growth

Vaccinex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.16% of the float of Vaccinex has been sold short.

Short Interest Ratio / Days to Cover

Vaccinex has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vaccinex has recently decreased by 20.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Vaccinex to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaccinex insiders have not sold or bought any company stock.

Percentage Held by Insiders

51.50% of the stock of Vaccinex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

50.11% of the stock of Vaccinex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VCNX Stock Analysis - Frequently Asked Questions

How have VCNX shares performed this year?

Vaccinex's stock was trading at $0.98 at the start of the year. Since then, VCNX shares have decreased by 7.1% and is now trading at $0.91.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, November, 8th. The company reported ($35.70) earnings per share for the quarter, beating the consensus estimate of ($60.90) by $25.20. The firm had revenue of $0.05 million for the quarter.

When did Vaccinex's stock split?

Shares of Vaccinex reverse split before market open on Tuesday, February 20th 2024.The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Vaccinex IPO?

Vaccinex (VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include Pfizer (PFE), VBI Vaccines (VBIV), OPKO Health (OPK), Plug Power (PLUG), Vaxart (VXRT), NIO (NIO) and SNDL (SNDL).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 7/18/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VCNX
• CIK: 1205922
• Web: www.vaccinex.com
• Phone: (585) 271-2700
• Fax: 585-271-2765
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($48.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.25 million
• Net Margins: N/A
• Pretax Margin: -4,787.89%
• Return on Equity: N/A
• Return on Assets: -383.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.77
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: $388 thousand
• Price / Sales: 5.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.59) per share
• Price / Book: -0.34

Miscellaneous

• Outstanding Shares: 2,600,000
• Free Float: 1,261,000
• Market Cap: $2.29 million
• Optionable: No Data
• Beta: 1.10